Immix Biopharma (NASDAQ:IMMX) Receives “Market Outperform” Rating from Citizens Jmp

Citizens Jmp restated their market outperform rating on shares of Immix Biopharma (NASDAQ:IMMX) in a report published on Friday morning,Benzinga reports. The firm currently has a $23.00 target price on the stock.

Other analysts have also issued research reports about the company. Morgan Stanley assumed coverage on Immix Biopharma in a report on Wednesday. They issued an “overweight” rating and a $20.00 price target for the company. HC Wainwright raised their price objective on Immix Biopharma from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Friday. Mizuho began coverage on Immix Biopharma in a research report on Monday, February 9th. They set an “outperform” rating and a $14.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.00.

Immix Biopharma Price Performance

IMMX stock opened at $8.15 on Friday. Immix Biopharma has a 12 month low of $1.34 and a 12 month high of $11.61. The firm’s 50-day moving average is $7.77 and its 200 day moving average is $5.24. The company has a market capitalization of $431.71 million, a PE ratio of -9.16 and a beta of 0.25.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.12). Sell-side analysts forecast that Immix Biopharma will post -0.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Immix Biopharma

Several institutional investors have recently bought and sold shares of IMMX. Allworth Financial LP bought a new position in Immix Biopharma in the fourth quarter worth approximately $30,000. Mathes Company Inc. bought a new stake in Immix Biopharma during the 4th quarter valued at $56,000. Balyasny Asset Management L.P. bought a new stake in Immix Biopharma during the 4th quarter valued at $67,000. Kera Capital Partners Inc. purchased a new position in shares of Immix Biopharma in the 4th quarter valued at $68,000. Finally, Squarepoint Ops LLC bought a new position in shares of Immix Biopharma in the 4th quarter worth $112,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.